In early April, Novartis drug Vanrafia won accelerated FDA approval as ... becoming the first FDA-approved treatment for C3 glomerulopathy, an ultra-rare kidney disease that can progress to ...

Novartis to buy Regulus for $0.8 billion upfront with potential for $1.7B total based on ADPKD drug milestone; deal set to ...

Novartis has claimed accelerated approval from the FDA for Vanrafia ... the treatment of rare kidney disease IgA nephropathy (IgAN). Vanrafia (atrasentan) is the first drug in the selective ...

Shares of Regulus more than doubled to $7.8. The deal, expected to bolster Novartis' lineup of kidney disease drugs ... the only treatment approved by the U.S. Food and Drug Administration in ...

Vera Therapeutics faces a pivotal moment with Phase 3 data expected soon. Depending on the result, the stock may spike or ...

If Regulus’ lead drug candidate, farabursen, gets regulatory approval ... Novartis – which has its U.S. headquarters in East Hanover – said the move will strengthen its lineup of kidney ...

Merck's Welireg wins FDA approval for rare PPGL tumors; Q1 2025 sales reach $137M, marking a 62% year-over-year increase.

Regulus forged ahead with plans to start a phase 3 trial that could support a filing for accelerated approval. Novartis has identified farabursen as a good fit for its burgeoning kidney disease ...

(Reuters) -Novartis has agreed to buy Regulus Therapeutics for up to $1.7 billion, giving the Swiss drugmaker access to an experimental drug to treat a life-threatening kidney disease. Under the ...